Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05114109 | Isatuximab in Type I Cryoglobulinemia(ICE) | unknown | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 0 |
| Nov 9, 2021 |
| clinicaltrials |
| NCT03670173 | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Shanghai 10th People's HospitalOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04891744 | Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | unknown | Phase 1 / Phase 2 | 48 | Li ZhengOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)(BuMelCarAuto) | unknown | Phase 1 / Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04762745 | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03669445 | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma(IFM2018-01) | unknown | Phase 2 | 45 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03977103 | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT | unknown | Phase 2 | 80 | University Of PerugiaOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04162119 | Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT04065308 | Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma(Dara_DCEP) | unknown | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT04063189 | Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | unknown | Phase 2 | 100 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT02954445 | A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03992170 | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive(DART4MM) | unknown | Phase 2 | 50 | Azienda Ospedaliera Universitaria SeneseOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03931421 | B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03940833 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT01240525 | Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers(ProT4) | unknown | Phase 2 | 114 | University College, LondonOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03697655 | Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma(PREDATOR) | unknown | Phase 2 | 274 | Polish Myeloma ConsortiumOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03767751 | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03746652 | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(DARIA) | unknown | Phase 2 | 50 | Hellenic Society of HematologyOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT03601624 | Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans(MM-POM-2018) | unknown | Phase 2 | 18 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del EstadoOTHER_GOV | 1 | Nov 14, 2018 | clinicaltrials |
| NCT02572492 | Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support(CARFI) | unknown | Phase 2 | 200 | Henrik GregersenOTHER | 5 | Aug 17, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03605056 | Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM | unknown | Phase 2 | 25 | Peng LiuOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT02158702 | Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03475628 | Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma(REBUILD) | unknown | Phase 2 | 57 | Hellenic Society of HematologyOTHER | 1 | Mar 23, 2018 | clinicaltrials |
| NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT03322735 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT02488382 | Lonquek for Autologous Stem Cell Mobilization | unknown | Phase 1 / Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Oct 17, 2017 | clinicaltrials |
| NCT02086942 | Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma. | unknown | Phase 2 | 94 | Yongping ZhaiOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT03244930 | Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation | unknown | Phase 2 | 20 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT02519114 | Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Maastricht University Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT01522872 | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 98 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 70 | OncotherapeuticsINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01886976 | Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138(CART-138) | unknown | Phase 1 / Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02624440 | Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma(SUTRICA) | unknown | Phase 2 | 300 | Henrik GregersenOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT01812096 | Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China(MM) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT00800059 | Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma(TMI-ASCT) | unknown | Phase 1 / Phase 2 | 27 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT02145715 | Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma(MUKsix) | unknown | Phase 1 / Phase 2 | 54 | Prof Jamie CavenaghOTHER | 1 | Jun 26, 2015 | clinicaltrials |
| NCT02093910 | Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT02270307 | MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis(MSC-CY) | unknown | Phase 2 / Phase 3 | 40 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 21, 2014 | clinicaltrials |
| NCT02248402 | Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma(Vax-DC/MM) | unknown | Phase 1 / Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT02027220 | Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma | unknown | Phase 2 | 60 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT01923935 | Busulfan and Melphalan Conditioning in Multiple Myeloma | unknown | Phase 2 | 105 | Chonnam National University HospitalOTHER | 1 | Aug 19, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Nov 23, 2021source: clinicaltrials